Data Presented at TCT 2018 Shows Use of Impella and Best Practices Increases Cardiogenic Shock Survival
September 24 2018 - 8:00AM
A new analysis of data from Abiomed's (NASDAQ:ABMD)
Impella® Quality (IQ) Database shows a relative increase of
24% in mean survival in acute myocardial infarction (AMI)
cardiogenic shock patients since Impella’s cardiogenic shock FDA
post-market approval. Part of the reason for the increase was a
near doubling in the number of hospital centers achieving a greater
than 80% survival to explant. This data was presented at the 30th
Transcatheter Cardiovascular Therapeutics (TCT) conference in San
Diego, Calif., by William O’Neill, MD, medical director of the
Center for Structural Heart Disease at Henry Ford Hospital in
Detroit.
“This real-world evidence shows an unprecedented increase in
survival outcomes for AMI cardiogenic shock patients and is a
result of the increased adoption of best practices for treating
cardiogenic shock,” said Dr. O’Neill.
The analysis is based on 11,566 AMICS patients treated with
Impella between April 2015 and June 2018 from Abiomed's IQ
Database. The IQ Database is a collection of observational, quality
assurance data on more than 95% of Impella patients since the
Impella heart pump’s introduction to the United States.
From the IQ Database, three best practices were identified and
adopted into treatment protocols at a growing number of hospitals
through the physician-led National Cardiogenic Shock Initiative
(NCSI). The best practices include placing Impella before
percutaneous coronary intervention (PCI), reducing use of
inotropes, and use of hemodynamic monitoring.
“We are seeing this improvement only a year and a half after
these best practices were identified and championed. In my career,
I haven’t before seen this kind of rapid change of outcomes in
interventional cardiology,” said Dr. O’Neill. “Historically,
survival rates for AMI cardiogenic shock have stagnated around 50%.
The adoption of these best practices and the improvement in
cardiogenic shock outcomes for so many patients is incredibly
gratifying.”
Separately at TCT, Dr. O’Neill also presented initial data from
the first 104 patients treated with the NCSI protocol. The data
showed a 77% survival to discharge with 99% native heart recovery.
The NCSI protocol includes placing Impella pre-PCI, reducing the
use of inotropes, and right heart hemodynamic monitoring.
“Taken together, these two data analyses demonstrate how best
practice protocols give us hope for improving survival rates in
cardiogenic shock,” said Michael R. Minogue, chairman, president
and chief executive officer of Abiomed. “Abiomed is committed to
advancing clinical research and innovation to improve outcomes for
our patients and send them home with their native heart.”
ABOUT IMPELLA HEART PUMPS
The Impella 2.5 and Impella CP devices are FDA approved to treat
certain advanced heart failure patients undergoing elective and
urgent percutaneous coronary interventions (PCI) such as stenting
or balloon angioplasty, to re-open blocked coronary arteries. The
Impella 2.5®, Impella CP®, Impella CP® with SmartAssist, Impella
5.0® and Impella LD® are FDA approved heart pumps used to treat
heart attack or cardiomyopathy patients in cardiogenic shock, and
have the unique ability to enable native heart recovery, allowing
patients to return home with their own heart. To learn more about
the Impella platform of heart pumps, including their approved
indications and important safety and risk information associated
with the use of the devices, please visit:
www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0,
Impella LD, Impella CP, Impella RP, and Recovering hearts. Saving
lives. are registered trademarks of ABIOMED, Inc. in the U.S. and
in certain foreign countries.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading
provider of medical devices that provide circulatory support. Our
products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For
additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
**For further information please contact:
Tom Langford Director, Communications and Public Relations
978-882-8408 tlangford@abiomed.com
Ingrid Goldberg Ward Director, Investor Relations 978-646-1590
igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024